Short Interest in Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Expands By 1,136.9%

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 184,300 shares, a growth of 1,136.9% from the March 31st total of 14,900 shares. Currently, 0.0% of the company's stock are short sold. Based on an average daily trading volume, of 254,300 shares, the short-interest ratio is currently 0.7 days.

Shionogi & Co., Ltd. Stock Down 0.5 %

OTCMKTS:SGIOY traded down $0.05 during trading hours on Thursday, hitting $8.29. 106,368 shares of the company's stock traded hands, compared to its average volume of 123,274. The firm has a market cap of $14.10 billion, a P/E ratio of 14.27, a P/E/G ratio of 2.37 and a beta of 0.21. Shionogi & Co., Ltd. has a twelve month low of $6.22 and a twelve month high of $8.72. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.01 and a current ratio of 7.64. The stock's fifty day moving average price is $7.80 and its two-hundred day moving average price is $7.29.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last posted its quarterly earnings results on Friday, January 31st. The company reported $0.16 earnings per share for the quarter. Shionogi & Co., Ltd. had a return on equity of 12.02% and a net margin of 35.53%. On average, research analysts expect that Shionogi & Co., Ltd. will post 0.66 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd.

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.